BETHLEHEM, Pa.--(BUSINESS WIRE)--Neuromonics today announced the initiation of the first post-market U.S. study, to evaluate long-term outcomes for the Neuromonics Tinnitus Treatment. This is an FDA-cleared therapy proven to interact, interrupt and desensitize tinnitus disturbance for long-term benefit. Unlike traditional therapies, the Neuromonics Tinnitus Treatment comprehensively addresses the neurological, psychological and audiological basis of tinnitus. Patient enrollment is now underway, and the first patient has started treatment at Silverstein Institute.
